➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Moodys
McKesson
Express Scripts
Medtronic

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

AJOVY Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Litigation for AJOVY

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company2018-09-27

See all AJOVY litigation

PTAB Litigation
PetitionerDate
Eli Lilly and Company2018-09-28

See all AJOVY litigation

Company Disclosures: US Patents for AJOVY

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Teva Pharms Usa AJOVY fremanezumab-vfrm INJECTABLE;INJECTION 761089 001 2018-09-14   Start Trial Rinat Neuroscience Corporation (South San Francisco, CA) 2025-11-14 RX company
Teva Pharms Usa AJOVY fremanezumab-vfrm INJECTABLE;INJECTION 761089 001 2018-09-14   Start Trial Labrys Biologics, Inc. (San Mateo, CA) 2025-11-14 RX company
Teva Pharms Usa AJOVY fremanezumab-vfrm INJECTABLE;INJECTION 761089 001 2018-09-14   Start Trial Teva Pharmaceuticals International GmbH (Jona, CH) 2034-03-21 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for AJOVY

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132019000000105 Italy   Start Trial PRODUCT NAME: FREMANEZUMAB(AJOVY ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1358, 20190401
2019C/524 Belgium   Start Trial PRODUCT NAME: GALCANEZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/18/1330 20181116
300997 Netherlands   Start Trial PRODUCT NAME: FREMANEZUMAB; REGISTRATION NO/DATE: EU/1/19/1358 20190401
2019C/521 Belgium   Start Trial PRODUCT NAME: FREMANEZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/19/1358 20190401
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.